Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.47 |
| ▸ | SKP1 | P63208 | 1/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29913781 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTMEN1KMT2ATSHR | |
| SCHEMBL27203577 | 0.95 | MAPT (0.56) | SMN1; SMN2MAPTMEN1KMT2ATSHR | |
| SCHEMBL24480734 | 0.90 | GPR119 (0.63) | SMN1; SMN2MAPTMEN1KMT2ATSHR | |
| SCHEMBL30602883 | 0.90 | GPR119 (0.63) | SMN1; SMN2MAPTMEN1KMT2ATSHR | |
| SCHEMBL25208908 | 0.89 | HRH3 (0.71) | SMN1; SMN2MAPTMEN1KMT2ATSHR | |
| SCHEMBL24649969 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPTMEN1KMT2ATSHR | |
| SCHEMBL14802434 | 0.88 | MAPT (0.59) | SMN1; SMN2MAPTMEN1KMT2ATSHR | |
| SCHEMBL18673194 | 0.88 | MAPT (0.59) | SMN1; SMN2MAPTMEN1KMT2ATSHR | |
| SCHEMBL22912831 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2MAPTMEN1KMT2ATSHR | |
| SCHEMBL29396475 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2MAPTMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606555-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2026-04-21 | — | — | US | disclosed |
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | REGENT OF THE UNIV OF MICHIGAN (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260007681-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | UNIV MICHIGAN (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260000676-A1 | CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4452256-B1 | METHODS OF TREATING BRAIN TUMOURS AND NEUROBLASTOMAS | ASTRAZENECA AB (SE) | 2025-12-10 | — | — | EP | disclosed |
| US-20250368615-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2025-12-04 | — | — | US | disclosed |
| EP-4652161-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | Uppthera, Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| US-20250346573-A1 | AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | CHENGDU EASTON BIOPHARMACEUTICALS CO LTD (CN) | 2025-11-13 | — | — | US | disclosed |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | ARVINAS OPERATIONS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
| WO-2018098296-A1 | PIPERAZINE DERIVATIVES AS SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC (US) | 2018-05-31 | — | — | WO | disclosed |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2018-05-24 | — | — | US | disclosed |
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, NR5A1, KLK3 | SMN1; SMN2 4302/4885MAPT 4164/4885MEN1 1746/4885 |
| US-20250368615-A1 | CHEMICAL COMPOUNDS | CYP11B2, CYP11B1, CYP4B1 | SMN1; SMN2 4768/4885MAPT 3228/4885MEN1 406/4885 |
| US-20180141923-A1 | SELECTIVE HDAC1,2 INHIBITORS | HDAC1, HDAC2, HDAC11 | SMN1; SMN2 916/4885MAPT 1345/4885MEN1 4086/4885 |
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, ESRRB | SMN1; SMN2 2810/4885MAPT 4305/4885MEN1 3661/4885 |
| US-20260000676-A1 | CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, ESRRB | SMN1; SMN2 2280/4885MAPT 4644/4885MEN1 3970/4885 |
| US-12606555-B2 | Chemical compounds | PARP1, PARP11, PARP12 | SMN1; SMN2 4100/4885MAPT 4759/4885MEN1 3170/4885 |
| US-20260007681-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, AR | SMN1; SMN2 3411/4885MAPT 4310/4885MEN1 3918/4885 |
| US-20250346573-A1 | AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | PARP1, PARP8, PARP11 | SMN1; SMN2 2960/4885MAPT 622/4885MEN1 1393/4885 |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | WNT3A, WNT1, WNT3 | SMN1; SMN2 4423/4885MAPT 3765/4885MEN1 3006/4885 |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | SMN1; SMN2 2139/4885MAPT 2558/4885MEN1 2168/4885 |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | CRBN, CBL, MDM2 | SMN1; SMN2 1838/4885MAPT 2531/4885MEN1 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.